Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account
We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading
Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
SearchAbout VELSIPITYAbout VELSIPITYUncontrolled DiseasePatient ProfilesVELSIPITY OverviewMOAEfficacyEfficacyTrial DesignEfficacy DataSafetySafetyELEVATE UCENLIGHT UCStarting TreatmentAccess & SupportAccess & SupportVelsipityForMe Patient SupportEnrollment ResourcesResourcesResourcesRequest a RepEventsMaterialsVideos
Prescribing InformationMedication GuideIndication Patient SiteRequest Samples
In moderate to severe UC

One pill, once daily—no injections or infusions1

One pill, once daily—no injections or infusions1

  • One pill, once daily, same dose from the start1
  • A mean half-life of approximately 30 hours1
Icon of person
  • Conduct one-time pre-initiation screen*
  • VelsipityForMe offers flexible pre-initiation and financial support for eligible, commercially insured patients
There are some tests needed prior to starting treatment, while others can be conducted after treatment initiation.
Dosing & Administration
Treatment Initiation
Getting your patients started on VELSIPITY (etrasimod)
Starting treatment1
One pill, once daily, same dose1
  • Complete health screenings—see Treatment Initiation tab
  • Recommended dose: 2 mg orally, once daily, with or without food
  • Initiation dose is the maintenance dose; no titration is required
  • Exclude patients who:
    • Had certain cardiovascular conditions, including stroke, in the last 6 months
    • Are currently taking antineoplastic, immunomodulating, or non-corticosteroid immunosuppressive treatments, or drugs that could slow heart rate or AV conduction
    • Are or who plan to become pregnant
Pill container iconDrug-drug interactions1
No known food or expected SSRI interactions1
  • May impact concomitant medications that are also metabolized via CYP2C8, CYP2C9, and CYP3A4 pathways
  • These can include medications in the following classes: anti-arrhythmic drugs and QT prolonging drugs; beta-blockers or calcium channel blockers; antineoplastic, immunomodulating, or non-corticosteroid immunosuppressive therapies; and inhibitors (eg, fluconazole) or inducers (eg, rifampin) of these CYP pathways
  • No known interactions with monoamine oxidase (MAO) inhibitors or tyramine
CYP=cytochrome P450; SSRI=selective serotonin reuptake inhibitor.
Calendar with clock iconStopping treatment1
A mean half-life of approximately 30 hours1
  • The mean half-life of VELSIPITY is approximately 30 hours
  • Lymphocyte counts returned to normal range in 90% of patients within 4 to 5 weeks of discontinuation
  • After the last dose:
    • Women of childbearing age should use contraception for 1 week
    • Patients should be monitored for signs and symptoms of infection for 5 weeks
    • Patients receiving concomitant immunosuppressants should be monitored for infectious complications for 5 weeks
Pill is not actual size.

Visit our Patient Profiles page to explore some hypothetical types of patients who may benefit from a treatment like VELSIPITY.

Learn how Dedicated Care Coordinators support timely treatment initiation
for eligible patients enrolled in VelsipityForMe.
Get the Details Loading
VELSIPITY (etrasimod) is indicated for adults with moderately to severely active ulcerative colitis.1References:VELSIPITY [prescribing information]. New York, NY: Pfizer Inc.; August 2025.Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171.Vermeire S, Rubin DT, Peyrin-Biroulet L, et al. Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. Supplementary appendix. BMJ Open Gastroenterol. 2025;12(1):e001516.Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):550-561.Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Supplementary appendix. Gastroenterology. 2020;158(3):550-561.
Drug-drug interactions1
  • May impact concomitant medications that are also metabolized via CYP2C8, CYP2C9, and CYP3A4 pathways
  • These can include medications in the following classes: anti-arrhythmic drugs and QT prolonging drugs; beta-blockers or calcium channel blockers; antineoplastic, immunomodulating, or noncorticosteroid immunosuppressive therapies; and inhibitors (eg, fluconazole) or inducers (eg, rifampin) of these CYP pathways
  • No known interactions with monoamine oxidase (MAO) inhibitors or tyramine
Before your patients start VELSIPITY, they’ll need to do some health screenings
1.Icon of checklistConduct one-time pre-initiation screen
Icon of droplet of blood and magnifying glassBlood Work
Learn more
  • WHAT: Complete blood count (CBC) with differential and liver function tests1

    If patients have already had these tests done within the last 6 months or after discontinuing prior therapy, they don’t need to have it done again.1
Icon of ECG and heartECG
Learn more
  • WHAT: One-time electrocardiogram (ECG) before starting treatment
  • WHY: To screen for preexisting cardiac conduction abnormalities. After taking the first dose of VELSIPITY, some patients in clinical trials saw a temporary slowing of the heart (including bradycardia) and transient AV conduction delays1
  • INCIDENCE:
    Bradycardia
    • In the pivotal clinical trials, 1% to 3% of patients taking VELSIPITY experienced bradycardia after taking the first dose1
    • This temporary slowing occurred on either the first or second day after starting treatment1
    • For those who experienced bradycardia, most did not experience symptoms and, for those who did, symptoms such as dizziness resolved without intervention1 
  • AV Block
    • In the VELSIPITY clinical trials, 0.7% and 0.8% of patients taking VELSIPITY experienced a Mobitz type I AV block1
    • These transient AV conduction delays occurred after the first dose on the first day1
    • All events of AV block in the pivotal clinical trials resolved2
    • No patients reported a Mobitz type II second or third-degree AV block in the clinical trial program1
Approximately 99% of patients cleared the ECG requirement 

across UC-1 and UC-2
3
Approximately 99% of patients cleared the ECG requirement
across UC-1 and UC-23
Approximately 99% of patients cleared the ECG requirement across UC-1 and UC-23
Medical History
Learn moreWHAT: 
  • Review patient's history for medications that may affect heart rhythm or may have immunosuppressive effects1
  • Confirm patient has a documented full course of VZV vaccination, a history of varicella (chickenpox), or is VZV antibody positive1
  • Confirm patient is up to date with current immunization guidelines1
2.Start first dose of VELSIPITY
Shortly after, or prior to, the start of treatment
Icon of skin and magnifying glass next to text reading "skin examination"Skin Exam
Learn more
  • WHAT: Obtain a skin examination for suspicious lesions. Assess for abnormalities and provide a baseline so any changes can be identified and evaluated as appropriate. Check to see if your patient completed an annual skin exam recently1
  • WHY: With S1P receptor modulators, the risk of cutaneous malignancies is increased in controlled trials, and cases of cutaneous malignancies were reported1
  • INCIDENCE: No cutaneous malignancies were observed across UC-1, UC-2, and UC-3. The VELSIPITY clinical trial program was limited in duration and not designed to assess for events of long latency such as malignancy2,4,5
Icon of eyeEye Exam
Learn more
  • WHAT: Patient should obtain an eye exam of the fundus, including macula, to establish a baseline. Check to see if your patient completed an applicable eye exam recently. Periodically conduct an evaluation of the fundus, including the macula, while on therapy and any time there is a change in vision1
  • WHY: S1P receptor modulators, including VELSIPITY, have been associated with an increased risk of macular edema1
  • INCIDENCE: Across UC-1 and UC-2, 0.4% (n=2) of VELSIPITY patients and 0.4% (n=1) of placebo patients were reported to have macular edema. All events of macular edema resolved. In UC-3, there were no reports of macular edema2,4,5
At-home and in-office support for completing these tests is available to
eligible,
* commercially insured patients
At-home and in-office support for completing these tests is available to eligible,* commercially insured patients
Example Text
At-home and in-office support for completing these tests is available to eligible,* commercially insured patients

    Pill is not actual size.

Eligibility required. Commercially insured patients only. Health screening coordination services are not available for patients enrolled in a state or federally funded prescription health insurance program, or patients who reside in MI, MN, or RI.CBC=complete blood count; VZV=varicella zoster virus.

Visit our Patient Profiles page to explore some hypothetical types of patients who may benefit from a treatment like VELSIPITY.

Learn more about VelsipityForMe offerings for eligible patients.*

Learn more about VelsipityForMe offerings for eligible patients.*

Get Patients Started Loading
Terms and Conditions apply.VELSIPITY (etrasimod) is indicated for adults with moderately to severely active ulcerative colitis.1References:VELSIPITY [prescribing information]. New York, NY: Pfizer Inc.; August 2025.Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171.Vermeire S, Rubin DT, Peyrin-Biroulet L, et al. Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. Supplementary appendix. BMJ Open Gastroenterol. 2025;12(1):e001516.Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):550-561.Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Supplementary appendix. Gastroenterology. 2020;158(3):550-561.
VelsipityForMe Patient Support
Complete the enrollment form to connect your patients with support.
Questions? Call 1-800-350-3080 (Monday-Friday, 8 AM-8 PM ET).
Enroll Your Patient Loading
Request VELSIPITY Samples
Register or sign in to check availability and request samples.
Order Now Loading

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-V1A-USA-1751
IndicationVELSIPITY® (etrasimod) is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.
Important Safety Information Contraindications
  • Patients in the last 6 months who experienced myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure
  • Patients with a history or presence of Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker
Infections 

VELSIPITY may increase the susceptibility to infections. Life-threatening and rare fatal infections have been reported in association with other sphingosine 1-phosphate (S1P) receptor modulators. Before starting VELSIPITY, obtain a recent (i.e., within 6 months) CBC, including lymphocyte count. Delay initiation of VELSIPITY in patients with an active infection until the infection is resolved. Consider interruption of treatment with VELSIPITY if a patient develops a serious infection. Continue monitoring for infections up to 5 weeks after discontinuing VELSIPITY.

  • Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the brain that typically occurs in patients who are immunocompromised, and usually leads to death or severe disability. PML has been reported in multiple sclerosis (MS) patients treated with S1P receptor modulators and has been associated with risk factors and duration of use. Longer treatment duration (≥18 months) increases the risk of PML. VELSIPITY is not indicated in MS. If PML is suspected, suspend VELSIPITY and discontinue if PML is confirmed by appropriate diagnostic evaluation. Immune reconstitution inflammatory syndrome (IRIS) has been reported in patients with MS treated with S1P receptor modulators who developed PML and discontinued treatment. Clinical decline may be rapid, can lead to serious neurological complications or death, and is often associated with characteristic MRI changes. Onset was generally within a few months after S1P receptor modulator discontinuation. Monitoring for IRIS should be undertaken.
  • Herpes simplex encephalitis, varicella zoster meningitis, and localized herpes viral infections have been reported with S1P receptor modulators. In UC-1, herpes zoster was reported in 0.7% of subjects treated with VELSIPITY and in none of the subjects who received placebo. Patients without a healthcare professional-confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against varicella zoster virus (VZV), should be tested for antibodies to VZV before initiating VELSIPITY. A full course of VZV vaccination for antibody-negative patients is recommended prior to commencing treatment with VELSIPITY.
  • Cases of fatal cryptococcal meningitis (CM) and disseminated cryptococcal infections have been reported with S1P receptor modulators. VELSIPITY treatment should be suspended until a cryptococcal infection has been excluded. If CM is diagnosed, appropriate treatment should be initiated.
  • VELSIPITY has not been studied in combination with anti-neoplastic, immune-modulating, or non-corticosteroid immunosuppressive therapies. Avoid concomitant administration of these therapies with VELSIPITY. 
  • Update immunizations according to current guidelines prior to VELSIPITY treatment. Avoid the use of live attenuated vaccines during and for 5 weeks after treatment with VELSIPITY. If live attenuated vaccine immunizations are required, administer at least 4 weeks prior to initiation of VELSIPITY.
Bradyarrhythmia and Atrioventricular (AV) Conduction Delays
Initiation of VELSIPITY may result in a transient decrease in heart rate and AV conduction delays. Before starting VELSIPITY, obtain an ECG to assess for preexisting cardiac conduction abnormalities. Seek advice of a cardiologist for patients with: significant QT prolongation; arrhythmia requiring treatment with Class Ia or Class III anti-arrhythmic drugs or QT prolonging drugs; unstable ischemic heart disease, Class I or Class II heart failure, history of cardiac arrest, cerebrovascular disease, or uncontrolled hypertension; resting HR<50bpm; history of symptomatic bradycardia, recurrent cardiogenic syncope, or severe untreated sleep apnea; history of Mobitz type I second-degree AV block in the absence of a functioning pacemaker.

Liver Injury
Elevations of aminotransferases may occur in patients receiving VELSIPITY. Obtain transaminase and bilirubin levels, if not recently available (i.e., within the last 6 months), before initiation of VELSIPITY or in patients who develop symptoms suggestive of hepatic dysfunction. Discontinue VELSIPITY if significant liver injury is confirmed. Use of VELSIPITY in patients with severe hepatic impairment is not recommended.

Macular Edema
S1P receptor modulators have been associated with an increased risk of macular edema. Obtain baseline evaluation of the fundus, including the macula near the start of VELSIPITY treatment. Periodically assess the fundus, including the macula, during treatment or if there is a change in vision. Consider discontinuing VELSIPITY if macular edema develops. 

Increased Blood Pressure 
VELSIPITY patients in clinical trials had average increases of 1 to 4 mm Hg systolic and 1 to 2 mm Hg diastolic blood pressure (BP). Increases were first detected after 2 weeks of treatment and remained within the specified average range of BP increases throughout treatment. Monitor BP during treatment with VELSIPITY and manage appropriately.

Fetal Risk
Based on animal studies, VELSIPITY may cause fetal harm. Advise pregnant females and females of reproductive potential of the potential risk to a fetus and to use effective contraception to avoid pregnancy during and for one week after stopping VELSIPITY. Pregnant females exposed to VELSIPITY are encouraged to contact the pregnancy registry by calling 1-800-616-3791.

Cutaneous Malignancies
Risk of cutaneous malignancies is increased in patients treated with S1P receptor modulators in clinical trials and cutaneous malignancies have been reported in the postmarketing setting. Skin examinations are recommended prior to or shortly after the start of treatment and periodically thereafter for all patients, particularly those with risk factors for skin cancer. Monitor for suspicious skin lesions. Limit UV exposure including phototherapy.

Posterior Reversible Encephalopathy Syndrome
Rare cases of posterior reversible encephalopathy syndrome (PRES) have been reported in patients receiving S1P receptor modulators. If a patient develops neurological or psychiatric symptoms/signs or any symptom/sign suggestive of an increase of intracranial pressure, or accelerated neurological deterioration, complete a physical and neurological examination promptly and consider an MRI. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, discontinue treatment with VELSIPITY.

Respiratory Effects
VELSIPITY may cause a decline in pulmonary function. Spirometric evaluation should be conducted during therapy if clinically indicated.

Unintended Additive Immune System Effects from Prior Treatment with Immunosuppressive or Immune-Modulating Drugs
When switching to VELSIPITY from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.

Immune System Effects After Stopping VELSIPITY
After stopping VELSIPITY, lymphocyte counts returned to the normal range in 90% of subjects within 4 to 5 weeks. Use of immunosuppressants within this period may lead to an additive effect on the immune system, and therefore monitor patients receiving concomitant immunosuppressants for infectious complications up to 5 weeks after the last dose of VELSIPITY.

Most Common Adverse Reactions

Most common adverse reactions reported in ≥ 2% of subjects and at a higher rate than placebo included: headache, elevated liver tests, dizziness, arthralgia, nausea, hypertension, bradycardia, UTI, hypercholesterolemia, and herpes viral infection.

Please see full Prescribing Information, including Medication Guide.
Indication

VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.